

# A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Sanofi
Enrollment	180 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Participant e1 year post bilateral lung transplantation at the time of screening
- Participants presenting with CLAD Stage 1 or 2: FEV1 from \>50% to 80% of post-transplant baseline at screening and at randomization
- Participants who have received at least 8 weeks of azithromycin (e250 mg/day, at least 3 times a week) prior to randomization

### Exclusion (3)

- FEV1 d50% of the post-transplant baseline value (CLAD 3 and 4)
- Lung function decline that can be explained by non-CLAD causes including but not limited to acute lung allograft rejection (\>A1), antibody-mediated rejection, airway stenosis, or tracheobronchomalacia
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

## Locations (80 total)

---

University of Alabama at Birmingham- Site Number : 8400026, Birmingham, Alabama, United States  
St. Joseph's Hospital and Medical Center- Site Number : 8400019, Phoenix, Arizona, United States  
University of California Los Angeles Medical Center- Site Number : 8400020, Los Angeles, California, United States  
... and 77 more locations